Prescription medicine
Insulin glargine Brand names: Lantus, Toujeo, Semglee, Rezvoglar, Langlara
Insulin glargine (Lantus) is a prescription medicine with an FDA approval on record since 2015. No generic is listed; pharmacies paid $2.90 per mL (Insulin glargine-yfgn u100 pen) in the October 7, 2026 NADAC survey.
- No generic listed
- A presentation discontinued
Check it at the source: the insulin glargine FDA label on DailyMed (effective June 16, 2026, Eli Lilly and Company); the BLA 205692 record on Drugs@FDA; every insulin glargine label on DailyMed.
Highlights of the record
FDA label of June 16, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageBASAGLAR ® is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
Forms and strengths
Injection (solution).
On the market
- Earliest approval on file
- December 16, 2015 Basaglar, Eli Lilly And Co; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 6 of which 0 under generic applications, 6 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $2.90 per mL Insulin glargine-yfgn u100 pen
- Shortage (FDA)
- None current 2 past records
- Recalls by its makers (FDA)
- 2 since 2022 2 Class I among all firms' recalls; latest July 5, 2022
- FAERS reports
- 245,619 through July 30, 2026
What is insulin glargine used for?
From the label: indications and usageBASAGLAR ® is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. BASAGLAR ® is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Not recommended for treating diabetic ketoacidosis. ( 1 ) Limitations of Use BASAGLAR is not recommended for the treatment of diabetic ketoacidosis.
Conditions named in the indications of insulin glargine's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Insulin Analog.
Source: FDA drug label (BASAGLAR KwikPen), Eli Lilly and Company, effective June 16, 2026 (SPL set 0ad21db3-2b1c-4ed9-a687-bdd6a74d0aae), via openFDA; the full label on DailyMed
What does the patient leaflet for insulin glargine say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What should I avoid while using BASAGLAR?While using BASAGLAR do not: drive or operate heavy machinery, until you know how BASAGLAR affects you. drink alcohol or use over-the-counter medicines that contain alcohol.
Source: FDA drug label (BASAGLAR KwikPen), Eli Lilly and Company, effective June 16, 2026 (SPL set 0ad21db3-2b1c-4ed9-a687-bdd6a74d0aae), via openFDA; the full label on DailyMed
Is there a generic for insulin glargine (Lantus)?
No generic insulin glargine is approved (Drugs@FDA, October 8, 2026).
- 2015 earliest approval on file
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for insulin glargine (Lantus)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $2.90 per mL (Insulin glargine-yfgn u100 pen), down 51% from $5.93 on October 8, 2025. The survey records the price, not the reason for a change; large moves often follow a new generic or a list-price change. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Insulin glargine-yfgn u100 pen (generic)
- Rezvoglar 100 unit/mL kwikpen (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Insulin glargine max solo u300 | Generic | $27.01 per mL | n/a | -26% |
| Insulin glargine solostar u300 | Generic | $27.01 per mL | n/a | -26% |
| Insulin glargine-yfgn u100 pen | Generic | $2.90 per mL | n/a | -51% |
| Insulin glargine-yfgn u100 vial | Generic | $6.08 per mL | n/a | -0.2% |
| Basaglar 100 unit/mL kwikpen | Brand | $20.94 per mL | n/a | no change |
| Lantus 100 unit/mL vial | Brand | $6.15 per mL | n/a | -0.1% |
| Lantus solostar 100 unit/mL | Brand | $6.17 per mL | n/a | no change |
| Rezvoglar 100 unit/mL kwikpen | Brand | $5.92 per mL | n/a | -0.2% |
| Semglee (yfgn) 100 unit/mL pen | Brand | $25.75 per mL | n/a | -0.4% |
| Semglee (yfgn) 100 unit/mL vial | Brand | $26.07 per mL | n/a | +0.6% |
| Toujeo max solostr 300 unit/mL | Brand | $91.30 per mL | n/a | no change |
| Toujeo solostar 300 unit/mL | Brand | $91.30 per mL | n/a | -0.1% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is insulin glargine in shortage?
No insulin glargine presentation is listed as in shortage in the FDA Drug Shortage Database (read October 8, 2026); its 2 records are all marked to be discontinued, the latest updated September 1, 2026. ASHP keeps a separate shortage list, which can differ.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Basaglar, Injection, U-100 Tempo Pen (NDC 0002-8214-05) | Eli Lilly and Co. | To Be Discontinued | October 24, 2025 |
| Rezvoglar, Injection, 100 [iU]/1 mL (NDC 0002-8980-05) | Eli Lilly and Co. | To Be Discontinued | September 1, 2026 |
Every insulin glargine presentation in the FDA shortage database
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
Has insulin glargine been recalled?
The FDA's Enforcement Report lists 2 recalls naming insulin glargine since 2022: 2 Class I (the most serious), 0 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| July 5, 2022 | Class I | Mylan Pharmaceuticals Inc | Labeling: Missing label: Label missing from some prefilled pens. |
| April 12, 2022 | Class I | Mylan Pharmaceuticals Inc | Labeling: Missing label on the vial |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the insulin glargine label say about other medicines?
The insulin glargine label names 17 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Albuterol | drug interactions | … progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones Intervention: Dose increases and increased frequency of glucose monitoring may be required when BASAGLAR is co-administered with these drugs. |
| Clonidine | drug interactions | Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of BASAGLAR Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. |
| Clozapine | drug interactions | Drugs That May Decrease the Blood Glucose Lowering Effect of BASAGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Danazol | drug interactions | Drugs That May Decrease the Blood Glucose Lowering Effect of BASAGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Disopyramide | drug interactions | Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. … |
| Epinephrine | drug interactions | … (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones Intervention: Dose increases and increased frequency of glucose monitoring may be required when BASAGLAR is co-administered with these drugs. |
| Fluoxetine | drug interactions | Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. … |
| Glucagon | drug interactions | Drugs That May Decrease the Blood Glucose Lowering Effect of BASAGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Isoniazid | drug interactions | Drugs That May Decrease the Blood Glucose Lowering Effect of BASAGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Lithium | drug interactions | Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of BASAGLAR Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. |
| Niacin | drug interactions | Drugs That May Decrease the Blood Glucose Lowering Effect of BASAGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Octreotide | drug interactions | Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. … |
| Olanzapine | drug interactions | Drugs That May Decrease the Blood Glucose Lowering Effect of BASAGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Pentoxifylline | drug interactions | Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. … |
Every other medicine the insulin glargine label names
| Medicine named | Section | What the label says |
|---|---|---|
| Pramlintide | drug interactions | … fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. … |
| Somatropin | drug interactions | … progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones Intervention: Dose increases and … |
| Terbutaline | drug interactions | … somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones Intervention: Dose increases and increased frequency of glucose monitoring may be required when … |
Source: FDA drug label (BASAGLAR KwikPen), Eli Lilly and Company, effective June 16, 2026 (SPL set 0ad21db3-2b1c-4ed9-a687-bdd6a74d0aae), via openFDA; the full label on DailyMed
What do FAERS reports show for insulin glargine?
The FDA Adverse Event Reporting System holds 245,619 reports that list insulin glargine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 13,523 are coded as a death and 64,727 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as insulin glargine?
13 other medicines are given the same way (subcutaneous) and in the same FDA class as insulin glargine or labeled mainly for the same use (type 2 diabetes), the same class first. Type 2 diabetes lists all 52 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Insulin aspart | Type 2 diabetes, Type 1 diabetes | none listed | $6.95 per mL 100 unit/mL vial | No current entry |
| Insulin lispro | Type 2 diabetes, Type 1 diabetes | none listed | $10.19 per mL 100 unit/mL kwikpen | A presentation being discontinued |
| Insulin degludec | Type 2 diabetes, Type 1 diabetes | none listed | $11.39 per mL 100 unit/mL pen | No current entry |
| Insulin detemir | Type 2 diabetes, Type 1 diabetes | none listed | n/a | No current entry |
| Insulin glulisine | Type 2 diabetes, Type 1 diabetes | none listed | $8.16 per mL 100 unit/mL vial | No current entry |
| Insulin degludec and liraglutide | Type 2 diabetes | none listed | $85.89 per mL 100 unit-3.6 mg/mL pen | No current entry |
| Tirzepatide | Type 2 diabetes | none listed | $538.68 per mL 10 mg/0.5 mL pen | No current entry |
| Liraglutide | Type 2 diabetes | 9 labelers | $31.41 per mL 2-pak 18 mg/3 mL | In shortage |
Every medicine labeled for the same conditions as insulin glargine
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does insulin glargine compare with medicines for the same use?
3 side-by-side pages set insulin glargine beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to insulin glargine
- 13 medicines for the same use
- Other insulin analogs
- the pharmacologic class, with prices and generics
- Insulin glargine side effects
- the label's list beside FAERS reports
- Insulin glargine shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other